An open label, multi-centre, dose escalation/expansion, phase1 study of IMU-201 (PD1-Vazz) a B-cell immunotherapy in adults with non-small cell lung cancer

  • Park, John (Primary Chief Investigator)
  • Chapman, Nicola (Clinical Trial Unit Staff)

Project: Research

Project Details

AcronymIMU.201.101
StatusActive
Effective start/end date1/08/20 → 30/06/25